Gene "FCER2"
Found 2 records
Gene information
Gene symbol:
FCER2
See related:
Ensembl: ENSG00000104921, Gene ID: 2208
Additive variants :
Undetected
Genetic interaction partners
No data
Modifier statisitcs
Record:
2 
Disorder:
1 
Vriant:
1 
Reference:
2 
Effect type:
Expressivity(2)  
Modifier effect:
Altered response to corticosteroid(1) ,Risk factor(1)  
Details：
  • Variant 1:
    FCER2:c.621+7T>C
    Gene:
    FCER2
    Genomic location:
    chr19:7755285
    dbSNP ID:
    rs28364072
    Target disease:
    Asthma(DOID_2841)
    Effect type:
    Expressivity 
    Modifier effect:
    Risk factor 
    Evidence:
    From review article 
    Effect:
    A novel variant in FCER2 was associated with increased risk of exacerbations in asthmatic children taking ICSs despite generally protective effects of this medication class.Variants in CRHR1, TBX21, and FCER2 contribute to variability in response for lung function, airways responsiveness, and exacerbations in patients taking inhaled corticosteroids.
    Reference:
    PMID19077707
    Title:
    Pharmacogenetics of asthma.
    Species studied:
    Human
    Abstract:
    Patient response to the asthma drug classes, bronchodilators, inhaled corticosteroids and leukotriene modifiers, are characterized by a large degree of heterogeneity, which is attributable in part to genetic variation. Herein, we review and update the pharmacogenetics and pharmaogenomics of common asthma drugs.
  • Variant 2:
    FCER2:c.621+7T>C
    Gene:
    FCER2
    Genomic location:
    chr19:7755285
    dbSNP ID:
    rs28364072
    Target disease:
    Asthma(DOID_2841)
    Effect type:
    Expressivity 
    Modifier effect:
    Altered response to corticosteroid 
    Evidence:
    From review article 
    Effect:
    Mutations in FCER2 is Associated with asthma exacerbations in the presence of corticosteroids
    Reference:
    PMID22455494
    Title:
    Genetic basis for personalized medicine in asthma.
    Species studied:
    Human
    Abstract:
    There is heterogeneity in patient responses to current asthma medications. Significant progress has been made identifying genetic polymorphisms that influence the efficacy and potential for adverse effects to asthma drugs, including; β(2)-adrenergic receptor agonists, corticosteroids and leukotriene modifiers. Pharmacogenetics holds great promise to maximise clinical outcomes and minimize adverse effects. Asthma is heterogeneous with respect to clinical presentation and inflammatory mechanisms underlying the disease, which is likely to contribute to variable results in clinical trials targeting specific inflammatory mediators. Genome-wide association studies have begun to identify genes underlying asthma (e.g., IL1RL1), which represent future therapeutic targets. In this article, we review and update the pharmacogenetics of current asthma therapies and discuss the genetics underlying selected Phase II and future targets.